Yaupon Therapeutics Inc.
This article was originally published in Start Up
Executive SummaryWith a comparatively small amount of private equity capital raised to date, specialty pharma Yaupon Therapeutics Inc. has quickly managed to establish a four-compound pipeline and to move two of its candidates-one a drug for methamphetamine addiction, the other a topical agent for cutaneous T-cell lymphoma--into the clinic.
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.